VolitionRX (VNRX) Corporate Presentation summary

Mission and business model

• Aims to save lives and improve outcomes for people and animals globally, focusing on cancer and sepsis diagnostics.

• Operates an asset-light, low-capex, low-opex model, leveraging commercial partnerships and out-licensing.

• Monetizes intellectual property through upfront, milestone, and recurring revenue from licensing agreements.

• Holds 71 patents with coverage up to 2044, supporting a strong IP position.

• Team has hundreds of years of combined experience and a track record of successful licensing.

Product portfolio and technology

• Offers a platform-agnostic, low-cost diagnostic technology adaptable to various workflows, including manual, automated, and point-of-care settings.

• Product suite includes Nu.Q® Cancer, Nu.Q® NETs, Nu.Q® Vet, Capture Seq, and Nu.Q® Discover, targeting multi-billion dollar markets.

• Nu.Q® Vet is available in the US, Europe, and Asia, with over 120,000 tests sold in 2024 and recommended for at-risk dogs.

• Nu.Q® Cancer addresses all five blood test applications in lung cancer, with direct sales expected in France in 1H 2026.

• Nu.Q® NETs is CE marked and under validation for over 20 clinical utilities, including sepsis and autoimmune diseases.

Commercialization and partnerships

• Commercialization strategy centers on licensing and partnerships with companies that have broad reach and large installed bases.

• Secured significant deals, including $10M upfront and $13M milestone payments from Antech, and partnerships with Fujifilm, IDEXX, and others.

• Recent agreements include research and commercial options with Werfen, Hologic, Diagenode, and HCL.

• In confidential licensing discussions with around 10 large diagnostic and liquid biopsy companies, with first deals signed in Q3 2025.

• Anticipates adoption into routine clinical practice and national screening programs starting in 2026.